ViCentra, the Dutch medical device company behind the Kaleido insulin patch pump, has secured an additional $13 million in funding, bringing its total Series D round to $98 million. The extension includes new investment from ROM Utrecht Region and a consortium of Dutch investors such as Venturing Tech, along with expanded participation from existing investor Innovation Industries. The additional capital follows the $85 million already raised in September 2025.
Advancing a New Era of Insulin Patch Pump Technology
ViCentra develops and manufactures Kaleido, a next-generation insulin patch pump designed to offer a compact, flexible, and user-friendly alternative to traditional insulin pumps. The device is widely recognised as one of the smallest, lightest, and most precise patch pumps available, supporting automated insulin therapy through integration with Diabeloop’s hybrid closed-loop algorithms, DBLG1 and DBLG2.
Kaleido is designed to blend personal technology aesthetics with high-performance medical engineering. It is built from premium materials and features interchangeable aluminium shells in ten different colours, allowing users to personalise their pump to match their lifestyle, comfort, and preference. Its modular design supports greater wearability and discretion, enabling people with diabetes to manage therapy seamlessly throughout the day.
Fueling Manufacturing Growth and Commercial Scale-Up
According to ViCentra’s CEO Tom Arnold, the past year marks a period of significant operational and commercial progress. The company has seen strong demand for Kaleido across Europe, accompanied by expanded manufacturing capabilities and deeper clinical integration.
The newly secured funding will enable ViCentra to scale its production capacity, ensuring the company can meet growing demand while maintaining strict quality and safety standards. This includes investment in manufacturing infrastructure, supply chain optimisation, and enhanced quality systems that support the company’s long-term growth trajectory.
ViCentra also plans to strengthen its commercial footprint in its core European markets — Germany, the Netherlands, and France. The company aims to improve customer support operations, refine onboarding processes for new users, and build more robust clinical and distribution partnerships across these regions.
Ambitious Growth Targets for 2026
With momentum building across Europe, ViCentra has set bold goals for the coming year. CEO Tom Arnold stated that the company’s priority for 2026 is to convert strong demand into high user satisfaction, delivering exceptional quality and reliability as Kaleido adoption accelerates.
ViCentra aims to nearly triple its European user base by the end of 2026, driven by improved availability of Kaleido pumps and expanded support for healthcare providers and diabetes clinics. The company will continue strengthening its service organisation to enhance user experience across onboarding, training, and long-term therapy management.
Preparing the Next-Generation Kaleido System for the U.S. Market
A major strategic aim for ViCentra is preparing its next-generation Kaleido system for entry into the United States, one of the world’s largest and fastest-growing insulin delivery markets. The new funding will support regulatory preparation, clinical planning, and early commercial groundwork required to introduce the system to U.S. users.
This includes adapting manufacturing processes for U.S. regulation, expanding engineering resources, and building early commercial infrastructure in anticipation of future approvals.
Positioning as a Leader in Wearable Diabetes Technology
The insulin delivery market is rapidly evolving toward smaller, more intuitive, and more personalised therapy solutions. Kaleido’s design philosophy, combining precision engineering, automation technology, and user-centric design, positions ViCentra as a standout innovator in this space.
With total Series D financing now at $98 million, ViCentra is well equipped to scale its operations, expand its geographic reach, and bring its newest generation of insulin pump technology to more people living with diabetes globally.
